A large clinical trial where pravastatin 20 mg/day was applied to women at high risk of preeclampsia from 35 to 37 weeks of gestation until delivery did not reveal such effects in vivo,3 while in our placental villous explant model, we only observed sFlt-1 and chemerin reductions at a concentration of 2000 μmol/L. The gene discussed is RARRES2; the disease is preeclampsia.